Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service (AGS)
Primary Purpose
Dysglycemia, Arthroplasty Complications
Status
Recruiting
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
AG service
Sponsored by

About this trial
This is an interventional treatment trial for Dysglycemia focused on measuring Perioperative complications, Dysglycemia management team, Nurse Practitioner, Hospital
Eligibility Criteria
Inclusion Criteria:
- Patients aged > 18 years
- Elective knee and hip arthroplasty patients
Exclusion Criteria:
- Patients who are incompetent to give informed consent
- Patients who are incompetent to assess their Quality-of-Life personally
Sites / Locations
- Päijät-Häme Central HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
AG service
Without AG service
Arm Description
In the "Active Comparator Arm": Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner.
In the "No intervention Arm": Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital.
Outcomes
Primary Outcome Measures
Survival
Improved survival
Secondary Outcome Measures
Complications
Less complications after AG-service
Full Information
NCT ID
NCT03306810
First Posted
September 19, 2017
Last Updated
October 10, 2017
Sponsor
Joint Authority for Päijät-Häme Social and Health Care
1. Study Identification
Unique Protocol Identification Number
NCT03306810
Brief Title
Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service
Acronym
AGS
Official Title
Recognition and Treatment of Dysglycemia in Elective Knee and Hip Arthroplasties. AGS - Acute Glucose Service
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Recruiting
Study Start Date
September 26, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Joint Authority for Päijät-Häme Social and Health Care
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
AGS (Acute Glucose Service ) is an inpatient glucose management service consisting of Nurse Practitioner and physician. Team manages not - consulted- based preoperative assessment, perioperative glucose control, patient education and supervision, but also transition of care postoperatively. The goal is to detect and treat dysglycemias , but also provide an active and constantly ongoing education to other hospital teams.
AGS improves better overall- survival of arthroplastic patients and is an effective way to recognize and treat dysglycemias and to organize constantly ongoing education.
Detailed Description
600 elective knee and hip arthroplastic patients are collected. 200 patients before AG- service will be compared to 400 patients after AGS. The latter group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years. Controls will be held after 3 months, 1 year and 5 years after operation including B-Hba1c, 15 D Quality of life assessment and patient interview.
There are several aims of the team and study: to detect, diagnose and optimize treatment (including medication) of diabetic/ dysglycemic patients from preoperative assessment 1 week before operation to postoperative care. With blood glucose target 42 - 86 mmol/mol results better overall survival, lesser complications (i.e. infections, cardiovascular or renal complications) and shorter length of hospital stay. Other aim is to find undiagnosed diabetics or those at risk of developing diabetes. One aim is to find risk factors, which lead to stress hyperglycemia during perioperative period or diabetes in 5 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysglycemia, Arthroplasty Complications
Keywords
Perioperative complications, Dysglycemia management team, Nurse Practitioner, Hospital
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
600 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
AG service
Arm Type
Active Comparator
Arm Description
In the "Active Comparator Arm": Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner.
Arm Title
Without AG service
Arm Type
No Intervention
Arm Description
In the "No intervention Arm": Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital.
Intervention Type
Other
Intervention Name(s)
AG service
Intervention Description
The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
Primary Outcome Measure Information:
Title
Survival
Description
Improved survival
Time Frame
1-5 years
Secondary Outcome Measure Information:
Title
Complications
Description
Less complications after AG-service
Time Frame
1-5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients aged > 18 years
Elective knee and hip arthroplasty patients
Exclusion Criteria:
Patients who are incompetent to give informed consent
Patients who are incompetent to assess their Quality-of-Life personally
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marianne Ylikoski, MD
Phone
+358447195268
Email
marianne.ylikoski@phhyky.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Raine Tiihonen, MD, PhD
Phone
+358444406151
Email
raine.tiihonen@phhyky.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marianne Ylikoski, MD
Organizational Affiliation
Päijät Häme Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Päijät-Häme Central Hospital
City
Lahti
ZIP/Postal Code
15850
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marianne Ylikoski, MD
Phone
+358447195268
Email
marianne.ylikoski@phhyky.fi
First Name & Middle Initial & Last Name & Degree
Raine Tiihonen, MD, PhD
Phone
+3584406151
Email
raine.tiihonen@phhyky.fi
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32615649
Citation
Ylikoski M, Jokinen JJ, Lahtela J, Kauppi MJ, Huhtala H, Immonen H, Tiihonen R. Perioperative hyperglycaemia in elective arthroplasties. Should we do better? Acta Anaesthesiol Scand. 2020 Oct;64(9):1253-1261. doi: 10.1111/aas.13666. Epub 2020 Jul 30.
Results Reference
derived
Learn more about this trial
Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service
We'll reach out to this number within 24 hrs